zolmitriptan has been researched along with Disease Models, Animal in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (8.33) | 18.2507 |
| 2000's | 2 (16.67) | 29.6817 |
| 2010's | 5 (41.67) | 24.3611 |
| 2020's | 4 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Abrams, RPM; Bachani, M; Balasubramanian, A; Brimacombe, K; Dorjsuren, D; Eastman, RT; Hall, MD; Jadhav, A; Lee, MH; Li, W; Malik, N; Nath, A; Padmanabhan, R; Simeonov, A; Steiner, JP; Teramoto, T; Yasgar, A; Zakharov, AV | 1 |
| Bukka, R; Khezri, FANZ; Lakshmi, CSR; Nargund, SL; Nidhi, M | 1 |
| Bennett, DJ; Birch, D; Heckman, CJ; Jiang, MC; Thaweerattanasinp, T; Tresch, MC; Tysseling, VM | 1 |
| Bansod, P; Swathi, KP; Tripathi, AS | 1 |
| Cotter, AR; Garcia, R; Leslie, K; Neisewander, JL; Olive, MF | 1 |
| Bhadauria, AS; Bhattachariya, B; Chakraborti, S; Gosipatala, SB; Kumar R, V; Kumar, D; Kumar, P; Kumar, U; Maity, B; Maurya, V; Pramanik, A; Saha, B; Saha, S; Singh, AK | 1 |
| Girotra, P; Kumar, G; Singh, SK | 1 |
| Heckman, CJ; Thaweerattanasinp, T; Tysseling, VM | 1 |
| Bourgoin, S; Hamon, M; Kayser, V; Latrémolière, A | 1 |
| Aubel, B; Bourgoin, S; Hamon, M; Kayser, V | 1 |
| Martino, G; Perkins, MN | 1 |
| Cambridge, D; MacLennan, SJ; Marston, C; Martin, GR; Whiting, MV | 1 |
12 other study(ies) available for zolmitriptan and Disease Models, Animal
| Article | Year |
|---|---|
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Drug Evaluation, Preclinical; High-Throughput Screening Assays; Immunocompetence; Inhibitory Concentration 50; Methacycline; Mice, Inbred C57BL; Protease Inhibitors; Quantitative Structure-Activity Relationship; Small Molecule Libraries; Vero Cells; Zika Virus; Zika Virus Infection | 2020 |
Pharmacokinetic study and brain tissue analysis of Zolmitriptan loaded chitosan nanoparticles in rats by LC-MS method.
Topics: Administration, Intranasal; Animals; Brain; Chitosan; Chromatography, Liquid; Disease Models, Animal; Male; Migraine Disorders; Nanoparticles; Oxazolidinones; Particle Size; Rats; Rats, Wistar; Tandem Mass Spectrometry; Tryptamines | 2020 |
Bursting interneurons in the deep dorsal horn develop increased excitability and sensitivity to serotonin after chronic spinal injury.
Topics: Action Potentials; Animals; Chronic Disease; Disease Models, Animal; Excitatory Postsynaptic Potentials; Interneurons; Mice; Mice, Inbred C57BL; Motor Neurons; N-Methylaspartate; Oxazolidinones; Posterior Horn Cells; Serotonin; Serotonin 5-HT1 Receptor Agonists; Spasm; Spinal Cord Injuries; Spinal Nerve Roots; Tryptamines | 2020 |
Activation of 5-HT 1b/d receptor restores the cognitive function by reducing glutamate release, deposition of β-amyloid and TLR-4 pathway in the brain of scopolamine-induced dementia in rat.
Topics: Amyloid beta-Peptides; Animals; Antioxidants; Brain; Cognition; Cognitive Dysfunction; Dementia; Disease Models, Animal; Glutamic Acid; Glutathione; Glutathione Peroxidase; Maze Learning; Memory Disorders; Oxazolidinones; Oxidative Stress; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1B; Scopolamine; Serotonin; Serotonin 5-HT1 Receptor Agonists; Superoxide Dismutase; Toll-Like Receptor 4; Tryptamines | 2021 |
Preclinical Evidence That 5-HT1B Receptor Agonists Show Promise as Medications for Psychostimulant Use Disorders.
Topics: Amphetamine-Related Disorders; Animals; Central Nervous System Stimulants; Conditioning, Operant; Disease Models, Animal; Dose-Response Relationship, Drug; Male; Methamphetamine; Motor Activity; Oxazolidinones; Pyridines; Random Allocation; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1B; Receptor, Serotonin, 5-HT1D; Reinforcement Schedule; Serotonin 5-HT1 Receptor Agonists; Tryptamines | 2017 |
Zolmitriptan attenuates hepatocellular carcinoma via activation of caspase mediated apoptosis.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Carcinoma, Hepatocellular; Caspase 3; Caspase 9; Cytokines; Disease Models, Animal; Glutathione; Lipids; Liver; Liver Neoplasms; Male; Nitric Oxide Synthase Type II; Oxazolidinones; Oxidative Stress; Proto-Oncogene Proteins c-bcl-2; Rats; Rats, Wistar; Tryptamines | 2019 |
Development of zolmitriptan loaded PLGA/poloxamer nanoparticles for migraine using quality by design approach.
Topics: Animals; Brain; Calorimetry, Differential Scanning; Disease Models, Animal; Drug Carriers; Drug Delivery Systems; Drug Design; Drug Liberation; Lactic Acid; Male; Mice; Migraine Disorders; Nanoparticles; Oxazolidinones; Particle Size; Poloxamer; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Rats; Serotonin 5-HT1 Receptor Agonists; Spectroscopy, Fourier Transform Infrared; Thermogravimetry; Tryptamines; X-Ray Diffraction | 2016 |
Firing characteristics of deep dorsal horn neurons after acute spinal transection during administration of agonists for 5-HT1B/1D and NMDA receptors.
Topics: Action Potentials; Animals; Disease Models, Animal; Excitatory Amino Acid Agonists; Interneurons; Mice, Inbred BALB C; Mice, Inbred C57BL; Microelectrodes; N-Methylaspartate; Oxazolidinones; Posterior Horn Cells; Receptor, Serotonin, 5-HT1B; Receptor, Serotonin, 5-HT1D; Receptors, N-Methyl-D-Aspartate; Sacrum; Serotonin 5-HT1 Receptor Agonists; Spinal Cord Injuries; Tissue Culture Techniques; Tryptamines | 2016 |
N-methyl-D-aspartate receptor-mediated modulations of the anti-allodynic effects of 5-HT1B/1D receptor stimulation in a rat model of trigeminal neuropathic pain.
Topics: Analgesics, Non-Narcotic; Animals; Cycloserine; Dihydroergotamine; Disease Models, Animal; Drug Synergism; Excitatory Amino Acid Antagonists; Hyperalgesia; Male; Motor Activity; Oxazolidinones; Pyrrolidinones; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Sciatica; Serotonin 5-HT1 Receptor Agonists; Trigeminal Neuralgia; Tryptamines | 2011 |
The antimigraine 5-HT 1B/1D receptor agonists, sumatriptan, zolmitriptan and dihydroergotamine, attenuate pain-related behaviour in a rat model of trigeminal neuropathic pain.
Topics: Animals; Dihydroergotamine; Disease Models, Animal; Male; Migraine Disorders; Oxazolidinones; Pain; Pain Threshold; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1B; Receptor, Serotonin, 5-HT1D; Receptors, Serotonin; Serotonin Receptor Agonists; Sumatriptan; Trigeminal Nerve Diseases; Tryptamines | 2002 |
Tactile-induced ultrasonic vocalization in the rat: a novel assay to assess anti-migraine therapies in vivo.
Topics: Administration, Oral; Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Diazepam; Disease Models, Animal; Drug Evaluation, Preclinical; Drugs, Investigational; Inflammation Mediators; Injections, Intraventricular; Injections, Subcutaneous; Ketorolac; Lipopolysaccharides; Male; Meningitis; Migraine Disorders; Morphine; Nociceptors; Oxazolidinones; Pain Threshold; Rats; Rats, Sprague-Dawley; Touch; Trigeminal Nerve; Tryptamines; Vocalization, Animal | 2008 |
Cranial vascular effects of zolmitriptan, a centrally active 5-HT1B/1D receptor partial agonist for the acute treatment of migraine.
Topics: Animals; Arteriovenous Anastomosis; Blood Flow Velocity; Carotid Arteries; Cats; Cerebral Cortex; Disease Models, Animal; Dogs; Male; Migraine Disorders; Oxazoles; Oxazolidinones; Receptor, Serotonin, 5-HT1B; Receptors, Serotonin; Serotonin Receptor Agonists; Tryptamines | 1998 |